CEVEC Pharmaceuticals GmbH
General information
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Str. 60 – 62
51105 Köln, North Rhine-Westphalia
Germany
Contact person: Nicole Faust, CEO
Company main phone: +49 (221) 46020800
Company main fax: +49 (221) 46020801
Website: https://www.cevec.com
Gottfried-Hagen-Str. 60 – 62
51105 Köln, North Rhine-Westphalia
Germany
Contact person: Nicole Faust, CEO
Company main phone: +49 (221) 46020800
Company main fax: +49 (221) 46020801
Website: https://www.cevec.com
| Year founded: | 2003 |
| Source of foundation: | Spin-off from university |
| Name of foundation source: | University of Cologne, Germany |
Corporate description / mission:
CEVEC Pharmaceuticals is a provider of cell technology for the manufacturing of advanced biotherapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors, viral vaccines, Exosomes and complex recombinant proteins. ELEVECTA® is specifically designed for AAV manufacturing, while CAP® addresses Adenoviral vectors, Lentiviral vectors, Oncolytic viruses and Exosomes. CAP®Go is the platform of choice for complex recombinant proteins.
CEVEC Pharmaceuticals is a provider of cell technology for the manufacturing of advanced biotherapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors, viral vaccines, Exosomes and complex recombinant proteins. ELEVECTA® is specifically designed for AAV manufacturing, while CAP® addresses Adenoviral vectors, Lentiviral vectors, Oncolytic viruses and Exosomes. CAP®Go is the platform of choice for complex recombinant proteins.
State of ownership: Private / independent
Headquarters: HQ: No
Headquarters: HQ: No
Remarks on ownership / listings
In Oct. 2022, Cytiva acquired CEVEC Pharmaceuticals GmbH
In Oct. 2022, Cytiva acquired CEVEC Pharmaceuticals GmbH
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Description of products:
RCA-FREE ADENOVIRAL VECTORS
STABLE AAV PRODUCER CELL LINES
VIRAL VECTORS, VACCINES AND EXOSOMES
GLYCO-OPTIMIZED PROTEINS
RCA-FREE ADENOVIRAL VECTORS
STABLE AAV PRODUCER CELL LINES
VIRAL VECTORS, VACCINES AND EXOSOMES
GLYCO-OPTIMIZED PROTEINS
Technology used:
ELEVECTA®
CAP®
CAP® Ad
CAP® Go
ELEVECTA®
CAP®
CAP® Ad
CAP® Go
Financing details
Financing details:
On April 2019, the company closed Series D financing round with new and existing investors. The funding will be allocated to the expansion and commercialization of CEVEC’s CAP®GT-based stable adeno-associated viral (AAV) vector production platform and to the broadening of the Company’s technology portfolio.
On April 2019, the company closed Series D financing round with new and existing investors. The funding will be allocated to the expansion and commercialization of CEVEC’s CAP®GT-based stable adeno-associated viral (AAV) vector production platform and to the broadening of the Company’s technology portfolio.
Collaborations & Clients
Partnering strategy / collaborations:
09 Feb 2017: CEVEC announces exclusive license agreement with NewLink Genetics for the use of its proprietary CAP(R)GT and CAP(R)GO cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections.
09 Feb 2017: CEVEC announces exclusive license agreement with NewLink Genetics for the use of its proprietary CAP(R)GT and CAP(R)GO cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections.
© 2024 Biotechgate by Venture Valuation